
Please try another search
BofA upgraded Universal Health (NYSE:UHS) to Buy from Neutral, with a $163 price target in a note Friday, with analysts saying they are optimistic about the combination of strong markets and a positive hospital macro backdrop.
"The combination of strong markets and a positive hospital macro backdrop (repricing, improving vols, moderating labor) gives us visibility into margins normalizing over time and creating a multi-year growth story," the analysts wrote.
The firm sees significant embedded earnings power from Acute Care normalization/repricing while they wait for the behavioral business to reaccelerate.
"Getting back to pre-COVID EBITDA margins implies a $600m+ (37%) opportunity for UHS vs 2023. UHS currently trades around 8x (near the midpoint of the 6-9x range over the past five years) but if margins and behavioral growth normalize there could also be upside to the multiple," said the analysts.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.